BPC-157 and the question of what a 'Body Protective Compound' actually is
Since the 1990s, a group around Predrag Sikirić in Zagreb has described a pentadecapeptide with an unusually broad range of preclinical effects. BPC-157 has become an internet legend — and a special case in academic medicine. A stocktake.
A sequence from gastric mucus
BPC-157 is a synthetic pentadecapeptide of 15 amino acids whose sequence was derived from an endogenous 'gastric protective factor' (Body Protective Compound, BPC) — a protein identified in the human gastric mucosa in the 1990s. Sikirić and his group in Zagreb postulated that a specific 15-amino-acid partial sequence of the BPC is sufficient to replicate the protective effects.
The first published description of the synthetic peptide appeared in 1993 in PubMed-listed journals. From the mid-1990s, an unusually consistent series of preclinical studies began: ulcer models (ethanol, indomethacin, stress), fracture healing, Achilles tendon ruptures, bone-implant integration, then increasingly systemic models — colitis, traumatic brain injury, cardiovascular insults. Over 20 years, Sikirić and co-authors have published more than 300 PubMed-listed papers on BPC-157.
The unusual breadth of the efficacy claims
What makes BPC-157 special in the peptide landscape is not a single efficacy claim but the breadth: angiogenic, anti-inflammatory, NO-modulating, dopaminergic-balancing, tendon/ligament/bone-promoting, gastroprotective. In the Sikirić studies the effect sizes are typically robust versus placebo or vehicle, and the safety profile is very favourable — even at high doses, few adverse events are reported in the animal studies.
From a methodological perspective, this constellation is striking. A substance that consistently shows positive effects in 12 different organ systems should normally have a clear molecular target — or the studies should be replicated by multiple independent groups. With BPC-157, neither is unambiguously met: the precise receptor or site of action is not established, and the overwhelming majority of published data comes from the Zagreb group.
What exists outside the Sikirić line
A number of studies from other groups have reproduced individual effects (e.g. on wound healing, tendon models, angiogenesis). These replications are not zero, but they are quantitatively small relative to the main corpus. They mostly concern individual models and not the systemic breadth of the original findings.
Human studies are extremely thin. There are individual small pilot studies (mostly open-label, unblinded), but no published methodologically sound RCT with clinical endpoints in humans. No Cochrane review or meta-analysis on BPC-157 exists.
„A substance whose efficacy claim is so broad that it covers nearly every indication is either an extraordinary therapeutic breakthrough — or a methodological problem."
The popular wave 2020–2024
From about 2020, BPC-157 was intensively discussed in English-language bio-hacking and sports forums. High-reach podcasts — particularly Andrew Huberman's appearances in 2022/2023 — brought the peptide to a six- to seven-figure audience. Influencer reports about tendon, tendon-sheath and Achilles recovery made BPC-157 a 'recovery' marker — and in parallel a standard offering of every US research-chemical vendor.
The FDA responded in 2023 with an explicit classification of BPC-157 as a 'Bulk Drug Substance' that does NOT belong on the compounding list (503A) — meaning it cannot legally be individually compounded by US pharmacies. This was a consistent regulatory tightening, not a new scientific finding.
What BPC-157 is — and is not
Open questions
- Which molecular mechanism (receptor, signalling pathway) explains the claimed systemic breadth of effect?
- Does an industry-linked or academic initiative exist for a controlled human study with clear endpoints?
- How are purity and identity problems of black-market products documented — and which proportion of those reports actually concern BPC-157 vs. impurities?
- What regulatory line do EMA/BfArM/MHRA take relative to the US-FDA classification?